Duan, Fei
The University of Texas MD Anderson Cancer Center
2 papers on CoChatORCID 0000-0002-4659-0144
Most cited papers
- Verified
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., et al. (2020) · Nature Medicine
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 318
- Verified
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
Kaseb, A. O., Hasanov, E., Cao, H. S. T., Xiao, L., Vauthey, J.-N., Lee, S. S., Yavuz, B. G., Mohamed, Y. I., Qayyum, A., Jindal, S., et al. (2022) · The Lancet Gastroenterology & Hepatology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 274
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free